Hematologic Oncology

Investigators successfully used PET/CT scanning to determine whether patients with stage IIB to IVB Hodgkin lymphoma should switch from ABVD to BEACOPP.

Catherine Smith, MD, discusses the evolution of FLT3 inhibition in AML and ongoing studies that are poised to potentially change practice.

Investigators are studying the value of polatuzumab vedotin in patients with intermediate- or high-risk diffuse large B-cell lymphoma.

PF-05280586, a biosimilar for rituximab (Rituxan/MabThera), delivered positive top-line results in the phase III REFLECTIONS B3281006 follicular lymphoma trial.

Gabriel Mannis, MD, discusses novel therapies shifting the treatment paradigm for patients with AML.

The CHOP-RIT regimen improved progression-free survival compared with R-CHOP alone in previously untreated patients with follicular lymphoma.

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, discusses developing active therapeutic combinations for the treatment of patients with acute myeloid leukemia